Other Information.
−Removed: Nothing to report.
+Added: In July 2020, we entered into a Severance Agreement and General Release with Timothy Morris, our former Chief Financial Officer, effective as of July 8, 2020, pursuant to which Mr.
+Added: Morris received the severance payment described in Section 6.2 of his Executive Employment Agreement effective August 14, 2017.
EXHIBIT INDEX
+Added: Amended and Restated Bylaws of Iovance Biotherapeutics, Inc.
+Added: (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on May 27, 2020).
+Added: Iovance Biotherapeutics, Inc.
+Added: 2020 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on June 9, 2020).
+Added: Iovance Biotherapeutics, Inc.
+Added: 2018 Equity Incentive Plan, as amended (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on June 9, 2020).
+Added: Second Amendment to the Lease Agreement, effective as of June 30, 2020, between Iovance Biotherapeutics, Inc.
+Added: and 300 Rouse Boulevard, LLC.
+Added: Severance Agreement and General Release, effective July 8, 2020, between Iovance Biotherapeutics, Inc.
+Added: and Timothy Morris.
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
3 unchanged sentences
The following financial information from the Quarterly Report on Form 10-Q of Iovance Biotherapeutics, Inc.
−Removed: for the quarter ended March 31, 2020, formatted in XBRL (eXtensible Business Reporting Language):
−Removed: (1) Condensed Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019;
−Removed: (2) Condensed Consolidated Statements of Operations for the three months ended March 31, 2020 and 2019;
−Removed: (3) Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2020 and 2019;
−Removed: (4) Condensed Consolidated Statements of Stockholders’ Equity as of March 31, 2020 and December 31, 2019;
−Removed: (5) Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020 and 2019;
+Added: for the quarter ended June 30, 2020, formatted in XBRL (eXtensible Business Reporting Language):
+Added: (1) Condensed Consolidated Balance Sheets as of June 30, 2020 and December 31, 2019;
+Added: (2) Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2020 and 2019;
+Added: (3) Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2020 and 2019;
+Added: (4) Condensed Consolidated Statements of Stockholders’ Equity as of June 30, 2020 and December 31, 2019;
+Added: (5) Condensed Consolidated Statements of Cash Flows for the three months ended June 30, 2020 and 2019;
and (6) Notes to Condensed Consolidated Financial Statements.
−Removed: Certain portions of the Exhibit have been omitted based upon a request for confidential treatment filed by us with the Commission.
−Removed: The omitted portions of the Exhibit have been separately filed by us with the Commission.
+Added: Certain portions of the Exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
Indicates a management contract or compensatory plan or arrangement.
+Added: Filed herewith.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Iovance Biotherapeutics, Inc.
−Removed: /s/ Maria Fardis
+Added: August 6, 2020
+Added: /s/ Maria Fardis, Ph.D., M.B.A.
+Added: Maria Fardis, Ph.D., M.B.A.
Chief Executive Officer (Principal Executive Officer)
−Removed: /s/ Timothy E.
−Removed: Chief Financial Officer (Principal Financial Officer)
+Added: August 6, 2020
+Added: /s/ Michael C.
+Added: VP, Finance (Interim Principal Financial Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.